BUZZ-Intellia falls as mid-stage data from gene therapy study fails to impress

Reuters10-24

** Gene editing firm Intellia Therapeutics' shares fall 18% to $16.38

** Company says its experimental gene therapy to treat a rare disorder called hereditary angioedema $(HAE)$ helped reduce monthly swelling attacks by up to 81% vs placebo in a mid-stage study

** HAE is characterized by unpredictable and frequent severe swelling of the skin, gastrointestinal tract, upper respiratory system, face and throat

** "We expect investors will view the ~75-80% reduction in HAE attacks as less than impressive in the context of the potential risks of in vivo gene editing and the competitive landscape in this indication" - brokerage Baird

** HAE treatments in the U.S. that are currently approved include drugs made by Takeda Pharmaceuticals and BioCryst Pharmaceuticals

** Including session moves, Intellia shares down ~46% YTD

(Reporting by Mariam Sunny in Bengaluru)

((Mariam.ESunny@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment